NASDAQ:ITCI

Intra-Cellular Therapies News Headlines

$43.18
+0.02 (+0.05 %)
(As of 06/18/2021 12:00 AM ET)
Add
Compare
Today's Range
$42.35
$43.27
50-Day Range
$29.30
$43.33
52-Week Range
$17.26
$43.82
Volume703,166 shs
Average Volume561,132 shs
Market Capitalization$3.51 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.33

Intra-Cellular Therapies (NASDAQ ITCI) News Headlines Today

SourceHeadline
Investors Who Bought Etherstack (ASX:ESK) Shares Five Years Ago Are Now Up 555%Investors Who Bought Etherstack (ASX:ESK) Shares Five Years Ago Are Now Up 555%
finance.yahoo.com - June 19 at 10:59 PM
Joel S. Marcus Sells 18,289 Shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) StockJoel S. Marcus Sells 18,289 Shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Stock
americanbankingnews.com - June 15 at 5:40 PM
Intra-Cellular Therapies (NASDAQ:ITCI) Sets New 1-Year High at $43.78Intra-Cellular Therapies (NASDAQ:ITCI) Sets New 1-Year High at $43.78
americanbankingnews.com - June 15 at 4:36 PM
Heres Why We Think Intra-Cellular Therapies, Inc.s (NASDAQ:ITCI) CEO Compensation Looks Fair for the time beingHere's Why We Think Intra-Cellular Therapies, Inc.'s (NASDAQ:ITCI) CEO Compensation Looks Fair for the time being
finance.yahoo.com - June 15 at 8:53 AM
Intra-Cellular Therapies (NASDAQ:ITCI) Stock Price Down 2.8%Intra-Cellular Therapies (NASDAQ:ITCI) Stock Price Down 2.8%
americanbankingnews.com - June 11 at 11:16 AM
Intra-Cellular Therapies (NASDAQ:ITCI) Hits New 12-Month High at $41.61Intra-Cellular Therapies (NASDAQ:ITCI) Hits New 12-Month High at $41.61
americanbankingnews.com - June 7 at 2:38 PM
CAPLYTA® (lumateperone) Schizophrenia Safety and Tolerability Profile Published in the Journal, International Clinical PsychopharmacologyCAPLYTA® (lumateperone) Schizophrenia Safety and Tolerability Profile Published in the Journal, International Clinical Psychopharmacology
finance.yahoo.com - June 7 at 12:05 PM
Intra-Cellular Therapies, Inc. (ITCI) CEO Sharon Mates on Q1 2021 Results - Earnings Call TranscriptIntra-Cellular Therapies, Inc. (ITCI) CEO Sharon Mates on Q1 2021 Results - Earnings Call Transcript
seekingalpha.com - May 12 at 9:19 AM
Intra-Cellular Therapies (ITCI) Reports Q1 Loss, Tops Revenue EstimatesIntra-Cellular Therapies (ITCI) Reports Q1 Loss, Tops Revenue Estimates
finance.yahoo.com - May 10 at 3:28 PM
Intra-Cellular Therapies Inc (ITCI) Q1 2021 Earnings Call TranscriptIntra-Cellular Therapies Inc (ITCI) Q1 2021 Earnings Call Transcript
finance.yahoo.com - May 10 at 3:28 PM
Intra-Cellular Therapies Reports First Quarter 2021 Financial Results and Provides Corporate UpdateIntra-Cellular Therapies Reports First Quarter 2021 Financial Results and Provides Corporate Update
finance.yahoo.com - May 10 at 7:41 AM
Intra-Cellular Therapies to Present at Two Upcoming Investor ConferencesIntra-Cellular Therapies to Present at Two Upcoming Investor Conferences
finance.yahoo.com - May 5 at 12:07 PM
Intra-Cellular Therapies to Host First Quarter 2021 Financial Results Conference Call and WebcastIntra-Cellular Therapies to Host First Quarter 2021 Financial Results Conference Call and Webcast
finance.yahoo.com - May 4 at 8:14 AM
Intra-Cellular Therapies Announces FDA Acceptance of CAPLYTA® (lumateperone) sNDAs for the Treatment of Bipolar DepressionIntra-Cellular Therapies Announces FDA Acceptance of CAPLYTA® (lumateperone) sNDAs for the Treatment of Bipolar Depression
finance.yahoo.com - May 3 at 8:04 AM
Earnings Preview: Intra-Cellular Therapies (ITCI) Q1 Earnings Expected to DeclineEarnings Preview: Intra-Cellular Therapies (ITCI) Q1 Earnings Expected to Decline
finance.yahoo.com - April 29 at 7:23 PM
Is ITCI Stock A Buy or Sell?Is ITCI Stock A Buy or Sell?
finance.yahoo.com - April 24 at 11:52 AM
Breakeven On The Horizon For Intra-Cellular Therapies, Inc. (NASDAQ:ITCI)Breakeven On The Horizon For Intra-Cellular Therapies, Inc. (NASDAQ:ITCI)
finance.yahoo.com - April 23 at 12:50 PM
Interesting ITCI Put And Call Options For June 18thInteresting ITCI Put And Call Options For June 18th
nasdaq.com - April 23 at 1:31 AM
Intra-Cellular Therapies Announces Investor Webcast and Presentations on Lumateperone Programs at the Upcoming American Psychiatric Association (APA) Annual MeetingIntra-Cellular Therapies Announces Investor Webcast and Presentations on Lumateperone Programs at the Upcoming American Psychiatric Association (APA) Annual Meeting
finance.yahoo.com - April 22 at 10:31 AM
Intra-Cellular Therapies Announces Board of Director Nominations in Advance of 2021 Annual MeetingIntra-Cellular Therapies Announces Board of Director Nominations in Advance of 2021 Annual Meeting
finance.yahoo.com - April 20 at 9:44 AM
Earnings Update: Heres Why Analysts Just Lifted Their Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Price Target To US$49.89Earnings Update: Here's Why Analysts Just Lifted Their Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Price Target To US$49.89
nasdaq.com - March 1 at 9:51 AM
Intra-Cellular Therapies, Inc.s (ITCI) CEO Sharon Mates on Q4 2020 Results - Earnings Call TranscriptIntra-Cellular Therapies, Inc.'s (ITCI) CEO Sharon Mates on Q4 2020 Results - Earnings Call Transcript
seekingalpha.com - February 27 at 7:19 PM
Intra-Cellular Therapies Inc (ITCI) Q4 2020 Earnings Call TranscriptIntra-Cellular Therapies Inc (ITCI) Q4 2020 Earnings Call Transcript
finance.yahoo.com - February 26 at 1:10 AM
Intra-Cellular Therapies (ITCI) Reports Q4 Loss, Tops Revenue EstimatesIntra-Cellular Therapies (ITCI) Reports Q4 Loss, Tops Revenue Estimates
msn.com - February 25 at 10:09 AM
Intra-Cellular Therapies Reports Fourth Quarter and Full-Year 2020 Financial Results And Provides Corporate UpdateIntra-Cellular Therapies Reports Fourth Quarter and Full-Year 2020 Financial Results And Provides Corporate Update
finance.yahoo.com - February 25 at 10:09 AM
Intra-Cellular Therapies Discloses New Drug Candidate For Dementia Related EpisodesIntra-Cellular Therapies Discloses New Drug Candidate For Dementia Related Episodes
finance.yahoo.com - February 24 at 1:50 PM
Intra-Cellular Therapies Announces Expansion of its Pipeline with the Introduction of a New Molecular Entity, ITI-1284Intra-Cellular Therapies Announces Expansion of its Pipeline with the Introduction of a New Molecular Entity, ITI-1284
finance.yahoo.com - February 24 at 8:49 AM
First Week of April 16th Options Trading For Intra-Cellular Therapies (ITCI)First Week of April 16th Options Trading For Intra-Cellular Therapies (ITCI)
nasdaq.com - February 22 at 5:56 PM
Intra-Cellular Therapies Files US Application For Expanded Use Of Lumateperone In Bipolar SettingsIntra-Cellular Therapies Files US Application For Expanded Use Of Lumateperone In Bipolar Settings
feeds.benzinga.com - February 22 at 2:38 PM
Intra-Cellular Therapies Applies for FDA Approval of CAPLYTA® (lumateperone) for the Treatment of Bipolar DepressionIntra-Cellular Therapies Applies for FDA Approval of CAPLYTA® (lumateperone) for the Treatment of Bipolar Depression
finance.yahoo.com - February 22 at 12:56 PM
Intra-Cellular Therapies to Present at the SVB Leerink 10th Annual Global Healthcare ConferenceIntra-Cellular Therapies to Present at the SVB Leerink 10th Annual Global Healthcare Conference
benzinga.com - February 19 at 9:39 AM
Intra-Cellular Therapies to Present at the SVB Leerink 10th Annual Global Healthcare ConferenceIntra-Cellular Therapies to Present at the SVB Leerink 10th Annual Global Healthcare Conference
finance.yahoo.com - February 19 at 9:39 AM
Intra-Cellular Therapies to Host Fourth Quarter and Full-Year 2020 Financial Results Conference Call and WebcastIntra-Cellular Therapies to Host Fourth Quarter and Full-Year 2020 Financial Results Conference Call and Webcast
finance.yahoo.com - February 17 at 12:04 PM
Intra-Cellular Therapies (NASDAQ:ITCI) Is In A Good Position To Deliver On Growth PlansIntra-Cellular Therapies (NASDAQ:ITCI) Is In A Good Position To Deliver On Growth Plans
finance.yahoo.com - February 10 at 9:24 AM
CAPLYTA® (lumateperone) Open-Label Safety Switching Study in Patients with Schizophrenia Published in the Journal, Schizophrenia ResearchCAPLYTA® (lumateperone) Open-Label Safety Switching Study in Patients with Schizophrenia Published in the Journal, Schizophrenia Research
finance.yahoo.com - January 21 at 8:31 AM
First Week of ITCI March 19th Options TradingFirst Week of ITCI March 19th Options Trading
nasdaq.com - January 15 at 2:39 PM
Intra-Cellular Therapies to Present at the 39th Annual J.P. Morgan Healthcare ConferenceIntra-Cellular Therapies to Present at the 39th Annual J.P. Morgan Healthcare Conference
finance.yahoo.com - January 5 at 12:42 PM
Noteworthy Wednesday Option Activity: WBA, CREE, ITCINoteworthy Wednesday Option Activity: WBA, CREE, ITCI
nasdaq.com - December 30 at 8:05 PM
Intra-Cellular Therapies Announces the Initiation of Clinical Trials for ITI-LLAI, a Long-Acting Injectable Formulation of Lumateperone for the Treatment of Schizophrenia and for ITI-333, a Novel Treatment for Opioid Use DisorderIntra-Cellular Therapies Announces the Initiation of Clinical Trials for ITI-LLAI, a Long-Acting Injectable Formulation of Lumateperone for the Treatment of Schizophrenia and for ITI-333, a Novel Treatment for Opioid Use Disorder
finance.yahoo.com - December 29 at 12:25 PM
The Play On Intra-Cellular Therapies NowThe Play On Intra-Cellular Therapies Now
seekingalpha.com - December 20 at 1:43 PM
Intra-Cellular Therapies Highlights Lumateperone Presentations at the 59th Annual Meeting of the American College of NeuropsychopharmacologyIntra-Cellular Therapies Highlights Lumateperone Presentations at the 59th Annual Meeting of the American College of Neuropsychopharmacology
finance.yahoo.com - December 9 at 8:31 AM
Intra-Cellular Therapies: Another Growth Cycle ApproachingIntra-Cellular Therapies: Another Growth Cycle Approaching
seekingalpha.com - December 4 at 1:42 PM
Intra-Cellular Therapies to Present at the Evercore ISI 3rd Annual HealthCONx ConferenceIntra-Cellular Therapies to Present at the Evercore ISI 3rd Annual HealthCONx Conference
finance.yahoo.com - November 30 at 11:35 AM
Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Reported Earnings Last Week And Analysts Are Already Upgrading Their EstimatesIntra-Cellular Therapies, Inc. (NASDAQ:ITCI) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates
finance.yahoo.com - November 12 at 10:25 AM
Intra-Cellular Therapies Inc (ITCI) Q3 2020 Earnings Call TranscriptIntra-Cellular Therapies Inc (ITCI) Q3 2020 Earnings Call Transcript
finance.yahoo.com - November 9 at 10:03 PM
Intra-Cellular Therapies EPS beats by $0.20, beats on revenueIntra-Cellular Therapies EPS beats by $0.20, beats on revenue
seekingalpha.com - November 9 at 12:00 PM
Recap: Intra-Cellular Therapies Q3 EarningsRecap: Intra-Cellular Therapies Q3 Earnings
finance.yahoo.com - November 9 at 12:00 PM
Intra-Cellular Therapies (ITCI) Reports Q3 Loss, Tops Revenue EstimatesIntra-Cellular Therapies (ITCI) Reports Q3 Loss, Tops Revenue Estimates
finance.yahoo.com - November 9 at 12:00 PM
Intra-Cellular Therapies, Inc. to Host Earnings CallIntra-Cellular Therapies, Inc. to Host Earnings Call
finance.yahoo.com - November 9 at 7:00 AM
Intra-Cellular Therapies Inc hosts conference call for investorsIntra-Cellular Therapies Inc hosts conference call for investors
markets.businessinsider.com - November 5 at 12:49 PM
This page was last updated on 6/20/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.